<unk>  (trade name Trogarzo) is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors. In a Phase III trial with 48 weeks of follow-up, HIV patients with multi-drug resistance tolerated<unk>  well in combination with other treatments, and 59% of patients achieved viral suppression. On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved<unk>  for multidrug-resistant HIV-1. It is used in combination with other antiretroviral drugs. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Ibalizumab
Risankizumab
Theralizumab
Ocrelizumab
Brolucizumab
Satralizumab
Inebilizumab
Reslizumab